Risk of cancer in transplant patients treated with recombinant growth hormone

  • Pierre Cochat
  • Marie-Hélène Saïd
  • Catherine Lesage
  • Cécile Gouffrant
  • Pascale Berlier
Part of the Transplantation and Clinical Immunology book series (TRAC, volume 27)

Abstract

Growth hormone (GH) is a potent stimulator of insulin-like growth factor- 1 (IGF-1), which in its turn has been proven to stimulate both cell proliferation and protein synthesis in various systems. Thus, the question may be raised whether the therapeutic use of GH, particularly in transplant patients, may increase the risk of developing malignant tumors or causing recurrence of a previous tumor that is thought to be under control [1].

Keywords

Growth Hormone Transplant Patient Growth Hormone Treatment Growth Hormone Therapy Bloom Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ritzén EM. Does growth hormone increase the risk of malignancies? Horm Res 1993; 39: 99–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Zadik Z, Estrov Z, Karov Y, Hahn T, Barak Y. The effect of growth hormone and IGF-1 on clonogenic growth of hematopoietic cells in leukemic patients during active disease and durning remission — A preliminary report. J Pediatr Endocrinol 1993; 6: 79–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Ogilvy-Stuart AL, Shalet SM. Tumour occurrence and recurrence. Horm Res 1992; 38 (suppl 1): 50–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Wilton R Adverse effect during growth hormone treatment: 5 years’ experience in the Kabi International Growth Study. In: Ranke MB, Gunnarsson R, editors. Progress in Growth Hormone Therapy — 5 years of the KIGS. Mannheim, Germany: J & J Verlag, 1994: 291–307.Google Scholar
  5. 5.
    Stahnke N. Leukemia in growth-hormone-treated patients: an update, 1992. Horm Res 1992; 38 (suppl 1): 56–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Butturini A, Bernasconi S, Izzi G, Gertner JM, Gale RP. Short stature, Fanconi’s anemia, and risk of leukaemia after growth hormone therapy. Lancet 1994; 343: 1576.PubMedCrossRefGoogle Scholar
  7. 7.
    Watanabe S, Mizuno S, Oshima LH, Tsunematsu Y, Fujimoto J, Komiyama A. Leukemia and other malignancies among GH users. J Pediatr Endocrinol 1993; 6: 99–108.PubMedCrossRefGoogle Scholar
  8. 8.
    Momoi T, Yamanaka C, Yorifuji T et al. Wilms tumour in a patient with growth hormone replacement therapy. Eur J Pediatr 1989; 149: 159–161.PubMedCrossRefGoogle Scholar
  9. 9.
    Bourguignon JP, Pierard E, Ernould C et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet 1993; 341: 1505–1506.PubMedCrossRefGoogle Scholar
  10. 10.
    Petersen BH, Rapaport R, Henry DP, Huseman C, Moore WV. Effect of treatment with biosynthetic human growth hormone on peripheral blood lymphocyte populations and function in growth hormone-deficient children. J Clin Endocrinol Metab 1990; 70: 1756–1760.PubMedCrossRefGoogle Scholar
  11. 11.
    Tönshoff B, Haffner D, Mehls O et al. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Kidney Int 1993; 44:199–207.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Pierre Cochat
  • Marie-Hélène Saïd
  • Catherine Lesage
  • Cécile Gouffrant
  • Pascale Berlier

There are no affiliations available

Personalised recommendations